Amylyx Pharmaceuticals proposes $350.0M common stock offering
Amylyx Pharmaceuticals (AMLX) announces a proposed $350.0M public offering of common stock, with proceeds to fund avexitide pre-commercial activities, R&D, and general corporate purposes.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.